1301 Factors driving disparities in glucocorticoid exposure among children with SLE in the CARRA registry

William Daniel Soulsby(University of California, San Francisco), Laura E. Schanberg(Duke University), Emily von Scheven(Unknown), Mary Beth F. Son(Boston Children's Hospital), Laura Berbert(Boston Children's Hospital), Aimee O. Hersh(University of Utah), Joyce C. Chang(Boston Children's Hospital), Rebecca Olveda(Medical Research Foundation), Jie He(Boston Children's Hospital), Edie Weller(Boston Children's Hospital), Andrea Knight(University of Toronto)
Unknown
May 1, 2024
10.1136/lupus-2023-lupus21century.89
Cited by 0

Related Papers

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
|New England Journal of Medicine|2020|2.7k
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
|Blood|2010|866
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
|JAMA|2021|852
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
|Arthritis & Rheumatology|2020|537
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465